Home Biosimilar Antibodies Apoptosis PD-1/PD-L1 Sintilimab (anti-PD-1)
For research use only. Not for use in humans.

Sintilimab (anti-PD-1)

Synonyms: PDCD1， CD279

Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.

Sintilimab (anti-PD-1)

Click to purchase the isotype control of Sintilimab (anti-PD-1)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A203502 Purity: 98.93% Protein concentration: 5 mg/ml Endotoxin Level: <1EU/mg
98.93

Specificity

Name Citation PD-1/PD-L1 interaction PD-1 PD-L1 PD-1/PD-L1 Others
GS-4224 0
INCB086550 1
BMS-1001 0
BMS-1166 8
PD-1/PD-L1 Inhibitor 3 14
BMS-1 13
BMS-202 28
CA-170 (AUPM-170) 0
SR 0987 1 IL17,RORγt
Spartalizumab (anti-PD-1) 3
Camrelizumab (anti-PD-1) 2
AUNP-12 5
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.
References

Product Details

CAS No. 2072873-06-2
Isotype Human IgG4, κ
Source CHO cells
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06365008 NOT_YET_RECRUITING Drug: Sintilimab+irinotecan+leucovorin folinate+fluorouracil Unresectable/Metastatic Gastric Cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 2026-06 PHASE2
NCT07768943 NOT_YET_RECRUITING Drug: Gemcitabine (GEM)|Drug: Etoposide Injection|Drug: Dexa Natural Killer/T-cell Lymphoma Fudan University 2026-09-01 PHASE2
NCT07567469 NOT_YET_RECRUITING Drug: Cemiplimab|Drug: Cemiplimab+Fianlimab Fixed Dose Combi High-Grade Glioma (HGG); Posterior Fossa-A Ependymoma Regeneron Pharmaceuticals 2026-08-31 PHASE1; PHASE2
NCT06794775 RECRUITING Drug: Nivolumab|Drug: Nivolumab + Ipilimumab Malignant Melanoma Stage III Hildur Helgadottir 2025-07-10 PHASE3
NCT07643623 RECRUITING Drug: tegafur, Gimeracil and Oteracil Potassium Capsules|Dru Resectable Gastric/Gastroesophageal Junction Adenocarcinoma Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. 2026-07-31 PHASE2; PHASE3
NCT06837948 NOT_YET_RECRUITING Drug: PM8002|Drug: Sintilimab|Drug: Nab-paclitaxel|Drug: Car Locally Advanced Non-Small Cell Lung Cancer Shanghai Pulmonary Hospital, Shanghai, China 2025-02-18 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-06-18)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.